Histone deacetylase activity is required for skin Langerhans cell maturation and phagocytosis

Journal of Dermatological Science

Volumn 65, Issue 2, 2012, Pages 152-155

  Qi, Ruiqun ^a,b   Liu, Min ^a   Gao, Xing Hua ^b   Yu, Fu Shin ^c   Chen, Hong Duo ^b   Lim, Henry W ^a   Zhou, Li ^a   Mi, Qing Sheng ^a  

^a HENRY FORD HOSPITAL   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Histone deacetylases; Langerhans cells; Maturation; Phagocytosis

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LANGERIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRICHOSTATIN A;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATOPIC DERMATITIS; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH DISORDER; HISTONE ACETYLATION; HUMAN; IMMUNOREGULATION; KERATINOCYTE; LANGERHANS CELL; LETTER; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; REGULATORY MECHANISM; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; LANGERHANS CELLS; MICE; MICE, INBRED C57BL; PHAGOCYTOSIS; SKIN; TIME FACTORS;

EID: 84856493535     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2011.11.009     Document Type: Letter

References (10)

1. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10:32-42.
2. Wang Z., Zang C., Cui K., Schones D.E., Barski A., Peng W., et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009, 138:1019-1031.
3. Kim T.H., Jung J.A., Kim G.D., Jang A.H., Cho J.J., Park Y.S., et al. The histone deacetylase inhibitor, trichostatin A, inhibits the development of 2,4-dinitrofluorobenzene-induced dermatitis in NC/Nga mice. Int Immunopharmacol 2010, 10:1310-1315.
4. Glauben R., Siegmund B. Molecular basis of histone deacetylase inhibitors as new drugs for the treatment of inflammatory diseases and cancer. Methods Mol Biol 2009, 512:365-376.
5. Merad M., Manz M.G., Karsunky H., Wagers A., Peters W., Charo I., et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 2002, 3:1135-1141.
6. Kaplan D.H., Kissenpfennig A., Clausen B.E. Insights into Langerhans cell function from Langerhans cell ablation models. Eur J Immunol 2008, 38:2369-2376.
7. Kaplan D.H., Li M.O., Jenison M.C., Shlomchik W.D., Flavell R.A., Shlomchik M.J. Autocrine/paracrine TGFbeta1 is required for the development of epidermal Langerhans cells. J Exp Med 2007, 204:2545-2552.
8. Kim E.S., Lee J.K. Histone deacetylase inhibitors decrease the antigen presenting activity of murine bone marrow derived dendritic cells. Cell Immunol 2010, 262:52-57.
9. Jux B., Kadow S., Esser C. Langerhans cell maturation and contact hypersensitivity are impaired in aryl hydrocarbon receptor-null mice. J Immunol 2009, 182:6709-6717.
10. Schuler G., Steinman R.M. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 1985, 161:526-546.